VPC
ARCT icon

Vestal Point Capital’s Arcturus Therapeutics ARCT Stock Holding History

Vestal Point Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-211,790
Closed -$2.24M – 73
2025
Q1 		$2.24M Buy
+211,790
New +$3.36M 0.16% 52

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vestal Point Capital's ARCT Position: Q2 2025 in Review

Vestal Point Capital sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 211,790 shares — an estimated $2.24M sold.

Vestal Point Capital first reported a position in ARCT in Q1 2025 and held it in 1 quarter. The position peaked at $2.24M in Q1 2025. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Vestal Point Capital reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Vestal Point Capital sold 211,790 Arcturus Therapeutics shares in Q2 2025, an estimated $2.24M.
  • Vestal Point Capital first reported a position in Arcturus Therapeutics in Q1 2025 and held it in 1 quarter.
  • Vestal Point Capital's Arcturus Therapeutics position peaked at $2.24M in Q1 2025.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.